At the end of 2025, Dr Rehan Haidry was invited as international faculty to the 42nd Turkish Society of Gastroenterology Meeting, one of the region’s most respected scientific gatherings bringing together leaders in gastroenterology, hepatology and advanced endoscopy.
In a well‑attended session, Dr Haidry delivered a presentation titled “Revolutionising Metabolic Disease Management Through Endoscopy”, exploring how endoscopic therapies are reshaping the landscape of metabolic and metabolic‑related disease.
The rising burden of obesity and Type 2 Diabetes is a global issue. Türkiye, like many countries, has seen a significant increase in metabolic disease over the past decade, driving demand for innovative, scalable and less invasive alternatives to bariatric surgery.
Against this backdrop, Dr Haidry outlined how metabolic endoscopy is emerging as a powerful new pillar in the management of obesity, metabolic syndrome and Type 2 Diabetes. He discussed how endoscopic interventions can target the physiological drivers of metabolic disease, offering patients effective alternatives to traditional bariatric surgery.
As part of the session, Dr Haidry presented early data on PIMA (Proximal Intestinal Mucosal Ablation) — a novel endoscopic technique developed at Cleveland Clinic London using radio‑frequency vapour ablation (RFVA) to remodel the duodenal mucosa and improve insulin sensitivity in patients with Type 2 Diabetes.
Dr Haidry’s invitation to speak in Türkiye reflects his growing international role in shaping the future of advanced endoscopic therapies. His session in Antalya generated strong engagement from clinicians and trainees eager to understand how metabolic endoscopy will influence future treatment pathways for obesity and Type 2 Diabetes.